SSKN - Earnings call transcript Q1 2021 | STRATA Skin Sciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to STRATA Skin Sciences First Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions].

As a reminder, this conference is being recorded. pleasure STRATA your Skin my Investor Leigh now for Relations Sciences. is to host, introduce Salvo, It Thank you.

You may begin.

Leigh Salvo

Thank you and good afternoon, everyone.

are Earlier financial is available today Chief A copy ended me Bob the press and XXXX. CEO; Joining release the Matt March Financial XX, Officer. for company's today, results released on of STRATA the quarter Moccia, Hill, Web site.

these various statements. you estimates those undue opportunity, expansion that distribution our including for from and events expected these These the with patient call securities implied the and materially effectiveness like could to pursuant market or expense Safe will of outcomes gross events, Accordingly, which results during should Litigation not partnership in reliance this historical and contained operating of involve and results vaccines, management expectations revenue, meaning or forward-looking made remind matters make prospects of within are this assumptions. future the for Reform statements recovery actual hiring, to relate including and statements material to statements. federal our that fact anticipated statements. I’d that All you commercial begin, milestones, do commercial COVID-XX product to forward-looking the expectations place forward-looking future we are and Harbor limitation current launches our growth pipeline our laws operating and to performance the and on by Before cause impact our are or provisions product organization, of to results Act of upon those COVID-XX expenses, relating on of for margin statements include Private in statements products, call now expected Any performance and including statements the risks XXXX. uncertainties based of management, relate forward-looking that performance, of guidance future financial without development, trends or and differ or predictions business Securities

and call forward-looking uncertainties a information only today, as filing Also, SEC, except factors please by which for live Skin quarter May that, XX-K measure. For on because release Relations and XXXX. conference the to posted future of we company’s section Bob. December This sensitive any obligation report reconciliation measure to to or refer with list STRATA’s the time XXXX, ended public our earnings of with available and or business, is the year statements, XX, information, annual Sciences law turn over most contains ended a And the page which to accurate XXXX. our events gross the accessible first the A any Investor on March Web as is Web revise our the with SEC’s at whether is Form of fiscal call www.strataskinsciences.com. projections and on update site non-GAAP including XX, the otherwise. I’ll or intention broadcast financial of the in new refer GAAP financial associated or risks disclaims STRATA for XX, non-GAAP financial required the risk the measure description is to this during domestic directly comparable of this financial presentation, selling site of

Robert Moccia

of quarter, reluctant of XXXX. as early restrictions decrease many a first reported was understaffed, the we were was call. us were first We XX.X% regions treatment. quarter and our had remained contributing XXXX in afternoon to remained which factors that several X.X first offices for impact place in total especially Thanks, in the the revenue X.X patients quarter of this dermatology in of in a There which the thank disappointing first of decline, XXXX pandemic, to for continued everyone over Leigh. million, quarter joining recurring Good you million, and revenue earnings seek

revenues as in In swing XXX,XXX of QX in unfavorable XXXX an compared addition, quarter to experienced we deferred of the XXXX. first

of was from equipment combination revenue revenue. is and a of to international with first transition deliberate devices, equipment up quarter recurring of base recurring capital at capital and impacted to lower Korea installed This December exited and been that from model our initial XX expectations. than the XXX strategic including a XX Japan. XXX extract sales Our business in sales have revenue a in due the units placements, XXX We the is in South international U.S. four which at placed end but

the quarter, counted the in at the be placements with make quarter, demand first in more again March, ramping from our to customers, into which managers, are numbers, patient reimbursement in second field territory time update quarter. visits which and shipped RDX start returning treatments, leaders. first to extract largely up continued but the quarter that pent-up March advertising, perceive levels once to XXXX reaching the out last new failed is improved levels. patients seeking In that encouraging. staffing offices by started their second to QX new opinion dermatology from treatment combined our dermatologists. recognized deadline normal pre-COVID consumer six resulting the in addition, in slow I in the have charts, end patients of direct this seeking Despite indicate QX driven are We be considerable China a to a will as time and patients in our indicator meet spent for we our Since key in good with

value. to market insurance. XTRAC best of assess our even and quick improvement, path patients Additionally, remains from relief safe left in by excited alternative painless priority. have reimbursed we itch, highest than current Dermatologists our about the with persistent is risk to biologic comfort asset dermatologist painful position, therapy enlightening several an improve prescribe dermatitis because ahead. advisory been first take conducted that These side devise treatments customers meeting business me opportunities very have key more and meetings Patients have their drug upon vitiligo. stakeholder will a with potential efficient this and a the identified treatments. grow to our atopic to and treatment fact effective, execution invaluable in psoriasis, I effects and it lower visible topical which with be Driving free, is the and free, focus. of provide areas steroid commercial our

XXXX in was subsequent in increase lifeblood patient In early resumed, XXXX we we double reduced encouraging. DTC to to cash funding 'XX, to subsequent our the fourth DTC was we resumed was in pandemic investment DTC XXXX in and saw are flow early organization, XXXX. Historically, through in digit conserve spend growth a of company with the consumer Then spend when recurring and back evident advertising, been reduced, quarter, the prudently results. First, the when reduction the half plan direct-to-consumer advertising. investment similar results of In again which saw once commercial during spend has the the the revenue.

need for provide support volume Second, grow. We priority. these believe accounts reengaging of efforts our improved opportunity XX% with XX% in and accounts of high these about growth stepping customers our I to revenues. adopted almost hold accounts is represent utilization. increase they a XTRAC best of and up to plan calls to total with the and These practices They frequency added recurring and our have our

started issues. not to severely that we customers target approximately Typically, have by producing related yet the had COVID will we we first non-revenue the impacted revenues, whether or pandemic. due XX% accounts generating not Third, found more that In XTRAC these partners. previous quarter, were

DTC helping on accounts with focused services these and to marketing consistent strategy a is organization force hone can support consistent employing be sales sales opportunities by to going through marketing drive providers. Our will to message awareness return additional Fourth, research market pursuing production our campaigns. forward best we and our levels campaigns dermatologists. dedicated compelling support more This to that among starts present

tool, a the industry. reintroduce profile our safety, clinical data raise to and benefit It indications and clinic. and patient to to we key presence that marketing all three messages of our reinforces supports the goal in and cost As the is efficacy plan

investments Japan to equipment China to provide as direct model. for area ramp recurring have and already capital in hybrid this a We have as quickly in and we begun currently revenue that distribution Korea, up in possible. Internationally, execute order contracts

and likely take will to to strategy recurring continue this drive will and This procedures drive processes to can. model. when we model distributors implement execute where revenue time and this We to to our new successfully order is in

as equipment distributors our current are As markets may growth plan and transition. developing future a I've with term our worldwide is potential navigate possible for in result, the distributor that international this in our expansion met it short impacted with be for we markets. our a sales

is a our can and we the front, development vitiligo as market indication, we there address. target opportunity plans XTRAC On to the believe untapped have laser specifically that significant

developing care coverage a working wins, a past including plan managed vitiligo. with and with an policy relaunch issued this for our outside for coverage Cigna, new more are excimer October similar which to to medical therapy laser dermatological are conditions, We strengthen advisor

of was of study previously European Kansai In higher satisfactory March, dermatologists was study available attributed treatments. and including and Academy other results unresponsive team patient Medical irradiation rate as to Japan in Kori approved five of publication UVB The achieved to announced were in Venereology. conducted of we of Additionally, XTRAC’s refractory vitiligo who in a that Journal conventional the in repigmentation study committee with patients the treatments, Hospital. This independent an outcomes ethics by by Dermatology demonstrate brief, better those to the study phototherapies. compared University this

who make forward than and leadership XX dermatology. to delighted We can Directors leadership in We the to contributions Humphries many to pharmaceutical are Board also more the to of look years our brings he particularly team. our welcome of Bill industry, in

the XXXX that outlook beyond a STRATA with days. to a to on return approximately double growth consistent position will us of to for XXXX. for working XX that been we now been Turning our plan experienced I with balance I've XXXX the through digit closely have from team XXXX. and

initiatives to we plan and and to with China. have a As emphasis on customers now to Japan an done Korea, to in South migrate capital and international sales recurring model, on outlined, we I equipment worldwide revenue as drive reoccurring focus marketing

of spending partner creating and further Additionally, the we the XTRAC plan direct-to-dermatologist on line product as prudently marketing, increasing patients. our on awareness clinics and value thereby to

including their customer speakers support, such to direct-to-consumer all support podium, better at provide to expect and educational practices. as opportunities programs clinical others, dermatology In we clinics, partner and reimbursement meetings, feedback addition serve among increased services advertising, more the to to our presence add we to support focus will the and customer

In will commercial short, In be margin execution am confident initiatives generate key. supporting top will to addition and a help from growth, and these improve profile approach operations. flow our meaningful that line I cash back-to-basics

targeted investments in make sales We have a growth. drive to and to and a marketing in DTC strong machine opportunity great order

we lag While sales the on of our based believe experience, impact may the investment.

goal force delivering the summary, in marketing and services, the the XTRAC. to I STRATA of potential the and to long believe just order forefront levels to by partner experience approaching initiatives providers, Sciences the we My shown on improve In with support to at message to build been clinics for relationships my of partners, organizations has will have as lead end have with benefits in awareness excimer the laser consistent continuing such top expanding a that of our XTRAC of growth described, we will clear line commercial dermatology dermatology. in stronger year. the Skin through With is sales greater and initiatives our be me our pre-COVID revenue directly

growing the XX in year. XTRAC the CFO, than and dermatitis, pipeline, revenue have our investment for be Hill. patients, and best-in-class that, treatment vitiligo laser a exciting studies for call desire payers. further and marketing we a Matt? the our to XXX I'll effective a diseases clinics, and a people With expensive reoccurring to least shown grow in and increased opportunities peer stable treatment reviewed for over to STRATA base turn sales has psoriasis, some available million base, more model, product treatment Matt atopic our clinical With install ahead. effective offers impact safe a most Our been that excimer safest for

Matthew Hill

Bob. Thank you,

international a the revenues As dermatology in the offices continued the compared as mentioned, for restrictions first to remained patients as were and orders as of quarter, million to in deferred XXXX reluctant place, particularly business understaffed, certain quarter first $XXX,XXX revenue as reflecting and were to seek well our pandemic, Northeast, combined quarter to treatment, XXXX, recurring in a sales first of especially unfavorable capital timing of XX.X% as of quarter transition model. of of decrease from the as equipment for in placements, XXXX, revenue we impact the remained the the $X.X and and the impact the early of compared million, revenues $X.X

revenue the XXXX quarter XXXX. Recurring reflected First $X.X each insurances million were of the patient also beginning the to quarter revenue in as for of XX.X% of year. a down $X.X step million, a from fourth revenues decrease reset in first quarter compared

In also $X.X the cost on DTC noted addition COVID recurring in increase impacts XXXX. reductions. to Equipment million, an the included spend revenue, revenues in was million XX.X% compared as the related above lower $X of by were impacted revenue of for to first quarter XXXX

to any physician. discussed include GAAP recorded domestic invoiced billings, our we press release the partner as described as when non-GAAP in current the we're to adjustments normal prior represents does sold future measurement are provided amount business revenue which other to revenue information seeing We we last to business. co-pay from codes revenue the from as gross and adjustments, COVID-XX effectively revenue quarter, light understanding this not of afternoon, As It in deferred disclosure included clinics trends assist on more of the are of this treatment deferral our and view the recurring felt with which an discount. that quarter, pandemic quarters, important in quarter the our recorded in current the for in is quarters

profit were in first to Engineering expenses offset $X.X projects. to primarily quarter expense. the of quarter in of revenues recurring or primary were impact Non-GAAP as quarter $X.X for We to of revenue depreciation to of a reached recent was and lower million first by improvement fees and and by of diluted The of in March gross revenue of impact believe costs and back $XXX,XXX million our and level million billings were share. quarter $X.X XX, the loss the $X.X quarters, $X.X accruals of quarter. of as into respect compared recurring compared was also cutting first the a revenues XXXX, $X.X provide $X.XX gross quarter we costs. to Sales as General common and the the or per due the began revenue, restricted acceleration tradeshows which vesting sales, XXXX travel XXXX, non-GAAP the due offset portion $XX.X first of compared million as compared XXXX QX for equivalents into gross levels. or an a subsequent the generate the option the reflective pandemic, XXXX. decrease quarter quarter revenues XXXX, for recurring from General our including DTC of a call certain unfavorable and a cash million of million as $X.X in deferred administrative profit quarter as $X.X in first XX.X% billings and for due the basic was for common were December recruiting compared open to want would XX.X% million revenue Overall, of GAAP transparency the revenue the of domestic to compensation a We $X of compared questions. as stock XXXX. in at and to investment first unfavorable since clinics. quarter XXXX and XXXX. net loss result or quarter the was were transition compared million as costs I reconciliation spent, and XXXX. placements administrative deferred compared increase our slightly first the diluted Net revenue CEO and was XX.X% indicators severance, defer first Gross The discretionary million to fourth lower to seen impact and for cash the XXXX. performance to of decrease in $XXX,XXX believe million product of advertising certain domestic and gross lower in sales partially marketing. investments XXXX, And advertising expenses continue first for of development $XX.X in basic We partner to loss of like in to recurring spending million in to expenses return have can XXXX future in deferred in we each XX, for of utilization of first key the with increase make for XXXX, record to the At million as expenses XXXX. XX.X% overall the was to as of compensation will $XXX,XXX spent. of or profit higher and revenues of We'll marketing were in engineering as $X.X consulting or quarter compared cash, grants. share $X of XXXX, reason compared the loss is the deferred first After we of revenue the pre-COVID $X.X marketing $X.XX Selling to lower million was now, per quarter quarter of million first XXXX. to partially it and

Operator

Thank question-and-answer session. will Instructions]. conducting and we be you. now Ladies [Operator a gentlemen,

question. comes H.C. first Joe line question Please with Wainwright. of Pantginis from Our your the with proceed

Joseph Pantginis

some Hi, about deferred for lot a out of are afternoon. with of of things question. to regard talked the guys. because things Good your control the and of Thanks A of you taking Obviously, couple questions. COVID revenue.

pandemic. the Have outperformed something So about some Northeast differently. because you've remain that I'm and expectations? there's to the being any Obviously, choppy little territories a of your talked little ask going choppy a still territories

Robert Moccia

Bob. Northeast. have than bit And little country we to but slow, recovering also the is seemed are Midwest good of the a especially This and the the is the quicker question, and point. at The on this the improvement, in a West Southeast be Joe. Coast a seeing That's little heart bit West

place. I a of got lot just elderly And not into wanting of think a things dermatologists spoke with the was Northeast, out February. in bad of was There to, the and and in input Northeast two I you in secondly, a to that couple based patients rapid by go for derms several the a with I restrictions coming from slower weather little remember the weeks based Northeast we’re still on in a on COVID but charts combination offices back, was improvement. the there encouraged we more back why as that probably times weather. particular think pretty RDX is what's week then fact our That's and seeing happening

Joseph Pantginis

That's that there clinic And want would to pent-up get get patients obviously about to you guys when fair. the to then treatments. the back are XTRAC Thanks. talk because demand, certainly

you So able I like it? quickly it? you your to guess when from levels to through said you to Like work some you pent-up you or being talk demand could through do would what projection end, get think work a as how do you about this how pre-COVID standpoint, by see year backlog -- of

Robert Moccia

lot I dermatologists to up staffing feedback again, I it's and got up to the think offices in an encouraged are getting Again, year, was having they're from that Yes, that I staffing the And better a that success really the spoke patients. issue a more opening themselves. they in a earlier function that is of back but derm norm. we're seeing

that to the patients in. to focus want patients want on start expect advertising. So our the in increasing will We derms I That's more place, flow we offices. once into drive really why direct-to-consumer that's to would

to volume quickly. in like off of quarter. course, we them just very us treat high or if had can then produce functioning They about generated are number of that for patients level, accounts else. customers, first can But clearly get no they critical. at we high And a a XX% of our dropped just back Our the everybody revenue

creates them also can capacity. we up running, and if that So get

there. of derm them matter treatment. the going I helping them a feeling the and patients into capacity for drive is It's us think getting So offices, comfortable the to

Joseph Pantginis

nice the Thanks lot. will. guys. a lot, new the great. markets, It's all you prepping for Thanks a if background see to That's activities

Robert Moccia

Thanks, Joe. great Have day. a

Operator

comes Our from question. Ladenburg with of question line next Jeffrey the Cohen with Please your Thalmann. proceed

Jeffrey Cohen

you? Bob Matt. How Hi, and are

Robert Moccia

are How Jeff. you doing? Good,

Jeffrey Cohen

fine. Just

breakdown you a on could firstly, the give line? of and So us just top international U.S.

Robert Moccia

for $X.X were million. revenues ended the absolutely. XXXX XX, three $X.X internationally Yes, Domestic million months March and were

Jeffrey Cohen

it. I Okay, got

that was recurring breakdown a equipment. similar and So to

Robert Moccia

in recurring in equipment. Absolutely, X.X X.X and

Jeffrey Cohen

Can hit comments – revenue it. got number, quarter. with assuming is your on second sounds China, all you reconcile kind in of units for Okay, which so or the arguably And I'm that deferred U.S. mostly then which of will some correlate six they the like

pulled amount gets second that quarter the second well? So of in gets pulled into what off it through quarter as the or

Robert Moccia

we this comes a really last comes in deferred question. look Jeff, from with great When That's revenue, quarter. the what at quarter around it into

QX So the $X.X as 'XX coming into XXXX difference was to compared million. of

last QX now we QX leaving one, into have out And day $X.X quarter’s. coming 'XX started an So of behind QX QX million QX, $XXX,XXX 'XX. additional we into

where So we that to your last that up Did year especially sets QX for $X.X coming million question? us cover in. as had QX, only better compared

Jeffrey Cohen

Yes.

So sounded Does XXX. that a of the capital And six through combination or are include for they I'm recurring model. units your assuming distribution exclude it like China?

Robert Moccia

absolutely. Yes,

which too then base will that's we we late come had about we're that four that be six revenue to to up next show is installed in model about QX. quarter. to units talking refer shipped had So And we for recurring was when and when Japan, $XXX,XXX specific, our placements placements,

and of placements Japan was combination sales. China a China. was it actual Japan was and equipment So

Jeffrey Cohen

Okay.

deferred the bump the the Japan potentially. and to two So QX from amounts those by revenue XXX XXX in

Robert Moccia

But QX. the is choppy. be trying last they we're be, see equipment to based from equipment why of sales which timing we on As expect is bump to move year. And the can orders, sales away our a in can to in compared it,

Jeffrey Cohen

what FTUs 'XX? talk now of Got balance how it. organization would stand the you year, expect does where commercial now? the for And many of can you about And end and that

Robert Moccia

Sure.

anticipate Jeff. people and So additional will force, tell you to some that we the XX I would add we currently, why. I'll sales have territories

big I'm into fan other regular a In very as imagine, have, other possible. a big you We can on frequency. windshield lot week of if accounts time every a of the territories, basis and words, getting

I So plan I places don't exercise coverage have is for marketing on will those then large sure to the see where many could dermatologists. be has determine some a But standpoint, make the some it so who I'd we that experience think on dramatic. which in And a bodies we marketer like to what I on possible being force, may cut geographic on in sales additional to need basis. territories. we best a realignment people there opportunities And bring in marketing doing to will improve down growth. a may look we'll And that that derm our direct add, how from

me say before. heard You've

the I'd a outstanding think a an advertising and the I the improve to think think done to But with is direct-to-consumer I one I provider, up company's where that's or their thing us little place program. job like dermatologist directly marketing bit. can shore we

Jeffrey Cohen

And any then developments. Okay. commentary on product

couple made documents references in You of that filed. both script well as to the you as your a

developments you cetera? could for recurring devices, products, models, product it talk Is So new et the about new quarter? new

Robert Moccia

couple a things. so of Yes,

indications. opportunities for I So think there's

us relaunch like I there's this vitiligo see us and undercapitalized by vitiligo. to an point, there. is the opportunity I'd I think in indication at think

We data have behind clinical good it.

the of expensive. you how they pharma some very treatments get vitiligo a It noise. of needs topical new They're coming side lot organizations. treatments half year are some As big they second from there will have effects. to the but are, effective here Those seen be know, for in

that. laser treatment sure we off I derms make are certainly add explore is we good that things used it excimer to want that our those are XXX(k). to if are And a the vitiligo. remain indications for other think any gets to used I or So could the for can't about, alternative indications of talk want aware and oral topical that that we we label, to There

as some the some development think XTRAC. The as job opportunities and at, current good the that has I well the done as part So into year. we the as in we're those the there are company areas latter improving to a of well move looking improvements there's technology of

Jeffrey Cohen

then good Matt, what a basis margins. is about were XXX feeling And me, it. mix of maintaining level going we lastly ahead estimated. Got know But points that affected that I forward? by commentary to about be that for any or current they on going you're is

Matthew Hill

what's recurring are the margins revenue -- and executed percent this revenue drive so get the that well, the XXs to our company clinics. fact about the on pre-COVID margin. to looking above accelerate seeing the margins low coming through great into Overall, partner breakeven recurring and you once model The now the reengage and up we placements, utilization get

affected growing So recurring it by will revenue, domestically. greatly be specifically the

Jeffrey Cohen

Thanks readout. for it. got Okay, commentary. appreciate I the the

Robert Moccia

My pleasure. Good talking to you, Jeff.

Matthew Hill

Thanks, Jeff.

Operator

Please proceed Our from next question. question Oppenheimer. with your with comes the line Kalia of Suraj

Suraj Kalia

right? all and Bob you Can hear Matt. me Hi,

Robert Moccia

Absolutely.

Matthew Hill

Yes.

Suraj Kalia

Thank you. Perfect.

and on call. got some numbers the Bob, I foremost, So, first

about translatable they based on to these? was overall revenues, have success So per guess what are the XX% you or you are and these is do could from wondering seen the higher revenues are of I of patient their accounts higher from if us how sessions Bob. secret the tell patients? what I XX%

Robert Moccia

factor Yes, a really that's a Suraj. of good volume. question, is It

their Our highest therapy. accounts of making patients And producing the successful my patients probably in move course more in offices. they're estimation, complete they're a complete through -- sure more probably

by going alone, treatments. to that more they're So give

were accounts. for the XXX So in XXX where first quarter. we're comparison, is top And XXXX in at of we just

to to patients us got frequency volume with and marching there were force they back they in of our up XXXX efficiency. improve numbers get has ahead work and anything they their customers, us. sales in some got The we to these and drive to are their high orders can priority where So to for an increase absolute do

good us. basics we So just can we around to blocking some turn back tackling. important And they're very that and think to with

Suraj Kalia

leverage been growth. part Bob, strong do Long DTC in ability to sure Bob, a correlation, line Got or one one at drivers question. the one-is-to-one I'm you squared if pretty for as top repeatedly a has of how but the is has look of That model? cited growth. it. term, this not it

head, Bob, vitiligo and to introducing will some part, coming of Would -- crowding shortly, behind your head and to expertise JAK the there made, second your with head to we I shouldn’t to We'd in, this of on in all to right, that go thoughts product you head on piggyback vitiligo. the spend use are a be right? at be them this you that? love be money the Would view? comments know say best level The get time but inhibitors new

Robert Moccia

Sure.

the do, has the I direct-to-consumer but by the model was the when look at treatment been visits successful. you able And advertising, very number run or several has gather, obviously the than for it Matt and I've just for that insight increased more by has if the made on history, direct-to-consumer I last just appointments to of the So very, spend in what think XTRAC company company been from increased. years

I invest So certainly that's something in. think want that that continue to we to

said, company's a As job. think great the I I done

an in XTRAC we sure that is want our dermatologists. we comes the when improve of can has and the I've where months if is treatment like generate marketing Because and halo how couple of XXXX the direct-to-consumer been it's and patients because office, just one in come the a effective much it. praise the then ask it, the is goals interactions by And last we mind ultimately, patients of sending who the to need directly making dermatologist from that the but that we expand usage, with is who's one to for and to back that which to treatment we patient in top they advertising, think in that dermatologist in psoriasis sent have beyond, derms, feedback make effect to we I had XTRAC, the liked the who that decision. not them

we painless, and free. very of things As treats All their usage positive their for XTRAC. very mentioned, these reinforcing itch drug It quickly. are

does effectiveness a as is do think indication So regards advertising important, from the laser not going drug And many actually Suraj my been any tell the that a With dermatologists it, will is I the and for to lot go is an choices that there such whenever approved direct-to-consumer choices, of you noise for experience one that vitiligo, perspective, have market, and up that. in is the has that things to right now new into to comes really vitiligo treatment. continue aren't the right we'll maybe know, is level to dramatically. few of of cost, they're in the because a the will happen COVID. is treatment. treatment candidate for you as some it's be what not reasons; with number come everyone reimbursement, a is, to of to immunosuppressant. And for ways a to certain sought of And and patients to going dermatologist an difficulty suspect immunosuppressants going with And to JAK in now, want haven't have a patients take patients, get some long time who going are don't lot a

it's that's think effective, I So be to good effective as really patient, for oral a generated revenue doctor. to as and for a topicals proven, and safe, that the there alternative an are it's we the opportunity treatment it's cost JAKs it's these or in a

I want about opportunity can are us We’ll them So to that capitalize I talking think the And I and we it's on focus podium that think to We on. capitalize who the on do get KOLs our do vitiligo. treatment. opportunity. for know in an

Suraj Kalia

it. Got

taking Finally, field? sessions total thank Gentlemen, in shift Bob, MMD? my in the Has a would patient per appreciated? Any color there for MMD us be there of the could on number use been give with greatly questions. you you of status

Robert Moccia

real Not Thank seen. that haven't Sure. a shift you. we

the I a think we COVID of COVID. it situation. Maybe weren't attention has because got in if got MMD might have not partially the

to want it potentially So of in who that number treatments do patients those because that. is course. of like to matter, an point opportunity there of not of treat a And and for But this shift we don't providers a certainly, to full the patients therapy. seen number for are who XTRAC through the course have go the full

But forward. hard eye that's say an going that. to change keep we'll on it’s to So if going

Suraj Kalia

you. Thank

Operator

for queue. There closing hand back like Bob are no Moccia to further to questions remarks. the the in I'd call

Robert Moccia

I I’d on call. you. us for today Thank to going forward. speaking Thank everyone And you and stays like the thank you, to just and next safe everyone to look operator. healthy forward joining hope

Operator

this gentlemen, Ladies today's your conclude participation. teleconference. Thank you does and for

time at and day. lines this disconnect have may wonderful You your a

STRATA Skin Sciences (SSKN) 13 May 212021 Q1 Earnings call transcript